Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction-associated steatotic liver disease: a comprehensive review

被引:0
作者
Ku, Jie-Lun [1 ]
Hsu, Jia-Rou [2 ]
Li, Yung-Tsung [3 ]
Wu, Li-Ling [2 ,4 ,5 ]
机构
[1] Natl Yang Ming Chiao Tung Univ, Coll Med, Sch Med, Taipei, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Dept & Inst Physiol, Coll Med, 155,Sec 2,Li Nong St, Taipei 112, Taiwan
[3] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei 100, Taiwan
[4] Natl Yang Ming Chiao Tung Univ, Hlth Innovat Ctr, Taipei, Taiwan
[5] Natl Yang Ming Chiao Tung Univ, Microbiota Res Ctr, Taipei, Taiwan
关键词
NUCLEAR RECEPTOR FXR; FARNESOID X RECEPTOR; FATTY LIVER; SALT HYDROLASE; INFLAMMATION; ANTAGONIST; CHOLESTEROL; ACTIVATION; FIBROSIS; TGR5;
D O I
10.1111/jgh.16750
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic disorder characterized by hepatic steatosis associated with metabolic abnormalities. Recent research has shed light on the intricate interplay among interleukin-1 receptor 1 (IL1R1), gut microbiota, and bile acids in the pathogenesis of MASLD. This review aims to provide a comprehensive overview of the current understanding of the role of IL1R1, gut microbiota, and bile acids in MASLD, exploring their interrelationships and potential mechanisms. We summarize the evidence supporting the involvement of IL1R1 in inflammation, discuss the influence of gut microbiota on bile acid metabolism and its influence on liver health, and elucidate the bidirectional interactions among IL1R1 signaling, gut microbiota composition, and bile acid homeostasis in MASLD. Furthermore, we highlight emerging therapeutic strategies targeting these interrelated pathways for the management of MASLD. Interleukin-1 receptor 1 (IL1R1), gut microbiota, and bile acids play interconnected roles in the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD). IL1R1 signaling is involved in hepatic inflammation and injury in MASLD, and genetic variations in IL1R1 can influence disease susceptibility. Gut dysbiosis, characterized by alterations in gut microbiota composition, is associated with MASLD and can affect bile acid metabolism. Bile acids, in addition to their role in digestion, have effects on hepatic lipid metabolism, inflammation, and fibrosis in MASLD. Targeting IL1R1, modulating gut microbiota through interventions like probiotics and fecal microbiota transplantation (FMT), and modulating bile acid metabolism hold promise for therapeutic interventions in MASLD. Further research is needed to elucidate the precise mechanisms underlying these interactions to develop effective targeted interventions for MASLD management. image
引用
收藏
页码:33 / 40
页数:8
相关论文
共 73 条
  • [1] Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
    Aron-Wisnewsky, Judith
    Vigliotti, Chloe
    Witjes, Julia
    Le, Phuong
    Holleboom, Adriaan G.
    Verheij, Joanne
    Nieuwdorp, Max
    Clement, Karine
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (05) : 279 - 297
  • [2] Nonalcoholic Fatty Liver Disease and the Gut Microbiome
    Boursier, Jerome
    Diehl, Anna Mae
    [J]. CLINICS IN LIVER DISEASE, 2016, 20 (02) : 263 - +
  • [3] The effect of synbiotics in patients with NAFLD: a systematic review and meta-analysis
    Cai, Jiacheng
    Dong, Jia
    Chen, Dahua
    Ye, Hua
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [4] Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis
    Cai, Jie
    Sun, Lulu
    Gonzalez, Frank J.
    [J]. CELL HOST & MICROBE, 2022, 30 (03) : 289 - 300
  • [5] The role of bile acids in cholestatic liver injury
    Cai, Shi-Ying
    Boyer, James L.
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
  • [6] Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD
    Carpino, Guido
    Del Ben, Maria
    Pastori, Daniele
    Carnevale, Roberto
    Baratta, Francesco
    Overi, Diletta
    Francis, Heather
    Cardinale, Vincenzo
    Onori, Paolo
    Safarikia, Samira
    Cammisotto, Vittoria
    Alvaro, Domenico
    Svegliati-Baroni, Gianluca
    Angelico, Francesco
    Gaudio, Eugenio
    Violi, Francesco
    [J]. HEPATOLOGY, 2020, 72 (02) : 470 - 485
  • [7] Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease
    Chao, Hsu-Wen
    Chao, Shi-Wei
    Lin, Heng
    Ku, Hui-Chen
    Cheng, Ching-Feng
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (02):
  • [8] Bile acid receptors FXR and TGR5 signaling in fatty liver diseases an therapy
    Chiang, John Y. L.
    Ferrell, Jessica M.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2020, 318 (03): : G554 - G573
  • [9] Bile acids and the gut microbiota: metabolic interactions and impacts on disease
    Collins, Stephanie L.
    Stine, Jonathan C.
    Bisanz, Jordan E.
    Okafor, C. Denise
    Patterson, Andrew D.
    [J]. NATURE REVIEWS MICROBIOLOGY, 2023, 21 (04) : 236 - 247
  • [10] Confalone Elena, 2010, Int J Biomed Sci, V6, P135